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ABSTRACT Virus infection of humans and livestock can be devastating for individu-
als and populations, sometimes resulting in large economic and societal impact. Pre-
vention of virus disease by vaccination or antiviral agents is difﬁcult to achieve. A
notable exception was the eradication of human smallpox by vaccination over 30
years ago. Today, humans and animals remain susceptible to poxvirus infections, in-
cluding zoonotic poxvirus transmission. Here we identiﬁed a small molecule, bisben-
zimide (bisbenzimidazole), and its derivatives as potent agents against prototypic
poxvirus infection in cell culture. We show that bisbenzimide derivatives, which pref-
erentially bind the minor groove of double-stranded DNA, inhibit vaccinia virus in-
fection by blocking viral DNA replication and abrogating postreplicative intermediate
and late gene transcription. The bisbenzimide derivatives are potent against vaccinia
virus and other poxviruses but ineffective against a range of other DNA and RNA vi-
ruses. The bisbenzimide derivatives are the ﬁrst inhibitors of their class, which ap-
pear to directly target the viral genome without affecting cell viability.
IMPORTANCE Smallpox was one of the most devastating diseases in human history
until it was eradicated by a worldwide vaccination campaign. Due to discontinuation
of routine vaccination more than 30 years ago, the majority of today’s human popu-
lation remains susceptible to infection with poxviruses. Here we present a family of
bisbenzimide (bisbenzimidazole) derivatives, known as Hoechst nuclear stains, with
high potency against poxvirus infection. Results from a variety of assays used to dis-
sect the poxvirus life cycle demonstrate that bisbenzimides inhibit viral gene expres-
sion and genome replication. These ﬁndings can lead to the development of novel
antiviral drugs that target viral genomes and block viral replication.
KEYWORDS DNA replication, antiviral agents, poxvirus, vaccinia virus, viral
transcription
Viral infections are difﬁcult to treat and prevent. Underlying technical reasonsinclude diagnosis and viral persistence and the fact that viruses occur in large
numbers, are genetically adaptable to environmental pressure, and are highly depen-
dent on their hosts (1–3). This makes it challenging to treat virus infections with
compounds that target viral factors such as enzymes or structural proteins. Compounds
directed against host factors required for infection potentially endanger the host,
although there is emerging evidence that clinically approved anticancer agents have
signiﬁcant efﬁcacy against viruses in postexposure regimens (4).
Today’s world population has become susceptible to poxvirus infection anew, after
the discontinuation of smallpox vaccination over 30 years ago. Notable poxvirus cases
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include variola virus, the causative agent of smallpox, which despite eradication is
ranked as a “category A pathogen” by the U.S. National Institute of Allergy and
Infectious Diseases. Further agents include the vaccinia virus (VACV) Cantalago virus
and cowpox viruses, which are contracted from infected animals and can cause fever
and lesions (5–9), and monkeypox, which has a mortality rate estimated around 10%
(10) and was responsible for the 2003 poxvirus outbreak in the United States (11, 12).
There are few current treatment options against orthopoxvirus infections. These include
the live attenuated VACV-based vaccines Dryvax and ACAM2000, which can have some
adverse effects, including fever, rash, encephalitis, and, in rare cases (1:1,000,000), death
(13, 14). Small molecule compounds against orthopoxvirus infections include cidofovir,
a nucleotide analog targeting the viral DNA polymerase (15), and ST-246 (tecovirimat
[TPOXX]), the most promising antipoxvirus drug, which inhibits virus cell-to-cell spread
(16–18). For both cidofovir and ST-246, poxvirus resistance has been reported (16, 19,
20). Remarkably, a single point mutation within the viral genome is sufﬁcient to give
rise to ST-246 resistance (16). In the face of the limited number of antipoxvirus drugs,
there is an obvious need for novel antivirals directed against poxviruses.
Targeting of the viral replication machinery by antivirals has been successfully
employed against RNA and DNA viruses (15, 21–24). Inhibition of viral polymerases and
helicases is effective as this strategy leads to sustained inhibition of genome replication,
thereby slowing the emergence of drug resistance mutations. To date, direct targeting
of viral genomes by antiviral agents has not been reported.
Bisbenzimides are a class of ﬂuorescent dyes that bind within the minor groove of
double-stranded DNA (dsDNA), preferentially to AT-rich regions (25–29). These com-
pounds have been used to drive proapoptotic and cytostatic activity in cancer cells (30,
31). In addition, bisbenzimide derivatives have been reported to indirectly modulate
mammalian and bacterial topoisomerase I and II activity (32–35). Yet their application
as antiviral agents has not been explored.
Here, we present evidence that a set of bisbenzimide derivatives that are commonly
known as Hoechst compounds (29, 36–38), display potent antipoxvirus activity far
separated from cell toxicity. Dissection of poxvirus temporal gene expression, uncoat-
ing, genome replication, and virus yield indicates that bisbenzimide-mediated antipox-
virus activity occurs through inhibition of viral intermediate (IG) and late (LG) gene
transcription as well as genome replication.
RESULTS
Bisbenzimides inhibit VACV infection. To determine if bisbenzimides have anti-
viral activity against VACV, we tested the abilities of three different bisbenzimides to
inhibit viral plaque formation assays: Hoechst 33342 (H4), Hoechst 33258 (H5), and
Hoechst 34580 (H8) (Fig. 1A). Conﬂuent monolayers of African green monkey kidney
(BSC40) cells were infected with serial dilutions of the VACV strain Western Reserve
(WR), which expresses enhanced green ﬂuorescent protein (EGFP) from an early/late
promoter (WR E/L EGFP) in the presence or absence of H4, H5, or H8. A known inhibitor
of VACV DNA replication, cytosine arabinoside (AraC) (39, 40), served as a positive
control in these experiments. At 24 h postinfection (hpi), plates were imaged for nuclei,
indicating cell numbers, and GFP expression, a surrogate for infection (Fig. 1B). The total
cell number and the number of infected cells were quantiﬁed using Plaque 2.0 (41) (Fig.
2). The Hoechst compounds displayed no apparent cell toxicity, with the exception of
H4 and, to a slight extent, H8, at the highest concentration tested, 20 M. With each
Hoechst compound, dose-dependent inhibition of VACV infection was observed. H4
was the most potent compound, causing a complete block of VACV infection at 2 M
regardless of virus concentration. H5 and H8 were less effective, both reaching com-
plete inhibition at 20 M (Fig. 2). These effects were not speciﬁc to BSC40 cells, since
similar results were obtained in L929 mouse ﬁbroblasts (data not shown). The data
show that the bisbenzimides H4, H5, and H8 exert potent inhibitory activity against
VACV infection with little cell toxicity when used at low micromolar concentrations.
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Bisbenzimides block intermediate and late but not early viral gene expression.
We next tested the impact of the most potent early/late viral gene expression inhibitor
(H4) and the least toxic compound (H5) on early and late viral gene expression. VACV
gene expression occurs in three temporal stages: early, intermediate, and late. Early
gene expression (EGE) occurs prior to DNA replication, while intermediate gene ex-
pression (IGE) and late gene expression (LGE) require DNA replication.
BSC40 or HeLa cells were pretreated with H4 or H5 and infected with recombinant
VACVs encoding EGFP under the control of an early (WR E EGFP) or late (WR L EGFP)
viral promoter. Cells treated with cycloheximide (CHX) and AraC served as positive
controls for inhibition of EGE and LGE, respectively (Fig. 3). Infection was quantiﬁed by
FIG 1 (A) Chemical structure, properties including partitioning coefﬁcient (LogP), and compound information of the
bisbenzimides used in this study. (B) Bisbenzimides (H4, H5, and H8) block VACV replication in tissue culture. BSC40 cells
were infected with a serial dilution of E/L EGFP VACV and treated with serial dilutions of H4, H5, H8, or AraC. Full-well
images show EGFP-expressing infected cells color coded by intensity (left panels). Nuclei were detected by staining with
Hoechst (right panels). Experiments were performed in triplicate; representative images are displayed. NoT, not drug
treated; NoV, not virus infected.
Bisbenzimides Inhibit Poxvirus Replication Journal of Virology
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ﬂow cytometry 8 hpi. In BSC40 cells, H4 treatment inhibited EGE up to 42% at 20 M
and completely blocked LGE at 800 nM and above. H5 on the other hand did not inhibit
EGE at any of the tested concentrations but showed a dose-dependent inhibition of
LGE of up to 90% from 2 M to 20 M (Fig. 3A). In HeLa cells, the trends of inhibition
by H4 and H5 were similar, but the compounds were more potent than in BSC40 cells,
with H4 resulting in complete inhibition of EGE at 4 M and LGE at 200 nM and with
H5 showing no impact on EGE but inhibiting LGE by 100% at 4 M (Fig. 3B).
The half-maximum and maximum effective concentration (EC50 and EC90, respec-
tively) for inhibition of EGE, IGE, and LGE were determined for H4 (Fig. 3C). HeLa cells
were pretreated with various concentrations of H4 and infected with WR E EGFP, WR I
EGFP, or WR L EGFP viruses. Consistent with the data in Fig. 2, the EC50 of H4 for EGE
was 800 nM and the EC90 was 1.6 M (Fig. 3C, blue line). H4 was even more effective
against IGE and LGE, with EC50 inhibition of IGE or LGE at 20 nM and EC90 at 80 nM (Fig.
3C, green and red lines). These results show that the bisbenzimide H4 is an effective
inhibitor of VACV IGE and LGE at nanomolar concentrations.
H4 blocks VACV plaque formation and reduces viral yield. Given the potent
effect of H4 on IGE and LGE, we next assessed the ability of H4 to inhibit plaque
formation and produce progeny. For plaque formation, monolayers of HeLa cells were
infected with 150 PFU of VACV in the absence (not drug treated [NoT]) or presence of
20 or 80 nM H4. At 72 hpi, monolayers were assessed for plaque formation by staining
the residual cells with crystal violet (Fig. 4A). In the presence of 20 nM H4, both the size
and number of plaques were strongly reduced, with a few small plaques detected. At
80 nM H4, no visible plaques were detected.
Next we assessed the impact of H4 on virus production in HeLa cells. In the presence
of 20 nM H4, the number of infectious particles was reduced by 1.5 logs at 24 hpi. In
the presence of 80 nM H4, virus production was reduced by 4 logs relative to the 24-h
yield in untreated cells (Fig. 4B). The results show that H4 effectively blocked VACV
plaque formation and the production of infectious particles, even over extended
periods (72 h) of incubation.
H4 targets an early stage of VACV infection. To address the stage of the virus life
cycle blocked by H4, we conducted add-in or washout experiments with H4 at different
times of infection. When 80 nM H4 was added as early as 6 hpi, virus yield was reduced
by 90% compared to that in the cells not drug treated (NoT) (Fig. 4C). Addition of H4
FIG 2 Quantiﬁcation of infected EGFP-expressing cells and total cell number (nuclei) from Fig. 1B. Gray
bars indicate the infection index, and red boxes indicate the cell number for each condition tested.
Experiments were performed in triplicate. Results are displayed as means  standard deviations (SD).
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at 9 hpi gave a 50% reduction, and addition at 12 hpi had no impact on virus yield (Fig.
4C). In washout experiments, only early washout of H4—for example, at 30 or 90 min
postinfection—partially rescued virus yield, whereas washout at later times essentially
had no rescue effects (Fig. 4D). These results indicated that H4 is most effective during
early stages of infection.
Pretreatment of puriﬁed VACV virions with H4 does not impact infectivity.
Remarkably, H4 had little impact on EGE but diminished virus yield at early infection
times, when events such as EGE occur. To resolve this puzzling notion, we tested if H4
directly affected the infectivity of virions. WR E EGFP and WR L EGFP viruses were
preincubated with H4 at 20 nM (EC50) or 80 nM (EC90), extensively washed to remove
residual bisbenzimide, and added to HeLa cells. Cells were harvested, and infection was
analyzed by ﬂow cytometry 8 hpi (Fig. 4E). The results showed that preincubation of
FIG 3 Bisbenzimides inhibit VACV intermediate and late gene expression. (A and B) BSC40 (A) or HeLa
(B) cells were infected with WR E EGFP (gray bars) or WR L EGFP (black bars) VACV. Cells were scored for
EGFP expression by ﬂow cytometry, and infected cells were quantiﬁed relative to untreated cells. CHX
and AraC served as controls for these experiments. (C) HeLa cells treated with various concentrations of
H4 were infected with WR E EGFP (blue line), WR I EGFP (green line), or WR L EGFP (red line), and the
percentage of EGFP-positive infected cells was quantiﬁed by ﬂow cytometry. These values were ﬁtted to
dose-response curves to estimate EC50 and EC90 values (dashed lines).
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virions with H4 had no signiﬁcant impact on either EGE or LGE. To conﬁrm these results,
a range of WR E/L EGFP virus concentrations were preincubated for various times with
2 M H4, a concentration that completely blocked EGE and LGE in HeLa cells (Fig. 3B
and C). Untreated (NoT) and pretreated virions were washed extensively before addi-
tion to cells. After 24 h, infection was quantiﬁed using the microscopy-based Plaque 2.0
assay (Fig. 4F). As expected, infection was dose dependent, yet even at 2 M H4, no
FIG 4 H4 inhibits plaque formation, reduces virus yield, and blocks early VACV infection without impacting particle
infectivity. (A) HeLa cells were infected with 150 PFU of WT VACV, and infection was allowed to proceed for 72 h. The plates
were stained with crystal violet to visualize plaques. (B) HeLa cells were infected with WT VACV (MOI of 1). Twenty-four
hours postinfection, cells were harvested and lysed and virus yield was determined by titration and plaque formation. (C)
HeLa cells were infected with WT virus (MOI of 1), and 80 nM H4 was added at the indicated time points. A sample
subjected to AraC addition at 6 hpi was included as a positive control for inhibition. Cells were harvested 24 hpi, and virus
yield was determined for each sample by serial dilution plaque assay. (D) HeLa cells were infected with WT virus (MOI of
1) in the presence of 80 nM H4. At the indicated time points, cells were washed, and infection was allowed to proceed.
A sample subjected to AraC washout at 6 hpi was included as a positive control for inhibition. At 24 hpi, virus yield was
determined for each sample by serial dilution plaque assay. (E) WR E EGFP (black bars) or WR L EGFP (white bars) virions
were preincubated with 20 or 80 nM H4 for 30 min at room temperature. Virus particles were washed three times and used
to infect HeLa cells. Samples were analyzed by ﬂow cytometry for infected EGFP-positive cells at 6 hpi (early) and 8 hpi
(late). a.u., absorbance units. (F) WR E/L EGFP virions were preincubated with 2 M H4 for 2, 3, or 4 h. Virions were washed
and used to infect HeLa cells prior to ﬁxation and analysis by Plaque 2.0 for total nuclei and EGFP-positive infected cells.
(A to F) All experiments were performed in triplicate; representative images are shown (A), or results are displayed as
means  SD (B to F).
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inhibition of VACV infection was observed. These results show that H4 does not directly
impact the infectivity of extracellular virions but rather acts on a critical intracellular
stage of the VACV life cycle.
H4 treatment does not impact VACV genome uncoating. Given that H4 had no
impact on EGE but effectively blocked IGE and LGE, we assessed genome uncoating
(reviewed in references 42 and 43), as it is a prerequisite for VACV genome replication
and subsequent IGE and LGE. Incoming VACV genomes released into the cytoplasm,
termed prereplication sites, can be visualized by immunoﬂuorescence directed against
the viral single-stranded DNA binding protein I3, or with click chemistry-based detec-
tion of single virus genomes (44–48).
Here we used I3 staining to test the inﬂuence of H4 on VACV prereplication site
formation. HeLa cells were infected in the presence of 20, 80, or 200 nM H4 and AraC,
ﬁxed at 5 hpi, and stained for I3 (Fig. 5A). AraC, which blocks viral replication post-
uncoating, and CHX, which blocks uncoating by inhibiting the synthesis of the VACV
uncoating factor (47), were included as controls. As expected, CHX prevented the
formation of prereplication sites, while AraC did not affect the number of I3 puncta. H4
did not affect the number of I3-positive prereplication sites (Fig. 5B). These results
show that H4 does not affect VACV genome uncoating even at concentrations
above those that inhibit IGE and LGE.
High concentrations of H4 inhibit VACV DNA replication. We next tested the
impact of H4 on VACV DNA replication site formation. Cells were infected in the
presence of 20, 80, or 200 nM H4 and assessed for replication site formation by staining
with 4=,6-diamidino-2-phenylindole (DAPI) at 8 hpi. As expected, untreated cells con-
tained large cytoplasmic VACV replication sites, while AraC-treated cells had none (Fig.
6A). The replication sites in H4-treated cells showed phenotypic differences from
control infections. At 20 nM, the replication sites appeared slightly smaller and more
diffuse, and at 80 nM and 200 nM, the size of the replication sites was reduced and
many small DAPI-positive puncta were seen (Fig. 6A). When the number of cells
FIG 5 H4 does not impact viral genome uncoating. (A) HeLa cells were infected with WT VACV (MOI of 10) in the presence
of 20, 80, or 200 nM H4 and AraC. Prereplication sites were visualized by immunoﬂuorescence staining against I3 followed
by confocal microscopy. CHX and AraC served as controls for uncoating and replication, respectively. (B) Quantiﬁcation of
prereplication sites per cell from panel A. (A and B) Experiments were performed in triplicate; representative images are
displayed, and results are shown as means  standard errors of the means (SEM). Scale bar, 10 m.
Bisbenzimides Inhibit Poxvirus Replication Journal of Virology
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FIG 6 H4 attenuates VACV IG/LG transcription and DNA replication in a dose-dependent fashion. (A) HeLa cells were
infected (MOI of 10) in the presence of 20, 80, or 200 nM H4. At 8 hpi, cells were ﬁxed and stained with DAPI and imaged
(Continued on next page)
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containing replication sites was quantiﬁed, without accounting for their size or number,
treatment with 20 or 80 nM H4 showed 14.9% and 20.7% decreases, respectively, while
treatment with 200 nM H4 decreased the number of cells containing replication sites
by 48.2% (Fig. 6B). We noticed that the replication sites seen in the presence of 200 nM
H4 were larger than the prereplication sites seen in the presence of AraC (Fig. 5A). This
suggested that H4 did not block DNA replication initiation, but rather acted after the
onset of replication.
To assess the impact of H4 on ongoing replication we used 5-ethynyl-20-
deoxyuridine (EdU) and click chemistry labeling (48). Cells were infected in the absence
or presence of 20, 80, or 200 nM H4, and the incorporation of EdU into viral replication
sites was assessed at 8 hpi (Fig. 6C). Untreated cells displayed numerous bright
EdU-positive replication sites. At 20 and 80 nM, the replication sites appeared less
numerous but brighter, while at 200 nM, small replication sites with little EdU incor-
poration were seen (Fig. 6C). Quantiﬁcation of the intensity of EdU per cell conﬁrmed
that nucleoside incorporation into viral replication sites was slightly reduced at 20 and
80 nM H4 and strongly reduced in the presence of 200 nM H4 to the levels seen in the
presence of AraC (Fig. 6D).
H4 blocks VACV DNA replication and IGE and LGE in a dose-dependent fashion.
Given the considerable size of the viral replication sites seen in the presence of 20 and
80 nM H4, we performed quantitative PCR (qPCR) to quantify VACV DNA synthesis in
the presence of H4 (49). Total DNA was extracted from cells infected with VACV at 8 hpi,
and the amount of viral DNA was quantiﬁed. While AraC blocked DNA accumulation as
expected, no defect in viral DNA content was seen in the presence of 20 nM H4, and
a modest decrease of 11% was observed at 80 nM H4 (Fig. 6E). VACV DNA accumulation
was reduced by 88% in the presence of 200 nM H4, consistent with the small replication
site phenotype observed in Fig. 6.
As VACV IGE and LGE occur after DNA replication, it was surprising to ﬁnd that DNA
accumulation was largely unimpeded in the presence of 20 and 80 nM H4, the
respective EC50 and EC90 against VACV infection. We reasoned that H4 may be
inhibiting transcription of VACV IGE and LGE at these low concentrations. Using
quantitative reverse transcription-PCR (RT-qPCR), we assessed the impact of H4 on the
accumulation of viral early (J2), intermediate (G8), and late (F17) mRNAs (Fig. 6F). While
H4 had little impact on early viral mRNA amounts, accumulation of intermediate mRNA
was diminished by 72% and that of late mRNA by 48% at 20 nM H4 (Fig. 6F). At 80 and
200 nM H4, intermediate mRNA accumulation was completely abrogated, and late
mRNA was reduced by 88 and 76%, respectively. These results indicate that the
bisbenzimide H4 impedes VACV infection by inhibiting two stages of the virus life cycle:
at low levels (20 nM and 80 nM), H4 inhibits IG and LG transcription, and at elevated
levels (200 nM), it inhibits VACV DNA replication as well as IG and LG transcription.
Poxvirus infection is acutely sensitive to the antiviral activity of H4. Given the
potent inhibitory effects of H4 on VACV transcription and replication, we asked if H4
could inhibit infection by other poxviruses. We tested three different parapoxviruses:
ORF-11, MRI-SCAB (50), and squirrelpox virus (SQPV) (51). For this, fetal lamb skin cell
monolayers were infected with these viruses in the presence of 20, 80, or 200 nM H4.
Cell monolayers were assessed for plaque formation at 3 days p.i. with VACV or ORF-11
FIG 6 Legend (Continued)
by confocal microscopy. Scale bar, 10 m. (B) The number of cells with cytoplasmic replication sites was quantiﬁed per
condition. AraC served as a control for inhibition of DNA replication site formation. (C) HeLa cells were infected (MOI of
10) in the presence of 20, 80, or 200 nM H4 and EdU. At 8 hpi, EdU incorporation was detected with a Click-iT EdU imaging
kit followed by confocal microscopy. Scale bar, 10 m. (D) The total intensity of EdU incorporation into replication sites
was quantiﬁed. (E) The amount of viral DNA from cells infected in the absence or presence of H4 at different concentrations
was quantiﬁed by qPCR at 8 hpi. AraC served as a control for inhibition of DNA replication. (F) The levels of early (J2),
intermediate (G8), and late (F17) viral mRNA from infected HeLa cells were quantiﬁed by RT-qPCR. Cells were infected in
the absence or presence of various concentrations of H4, and RT was performed at 2 hpi for J2, 4 hpi for G8, and 8 hpi
for F17. Results are displayed as the average abundance normalized to untreated samples. All experiments were performed
in triplicate; representative images (A and C) or means  SD (B and D to F) are displayed.
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and 7 days with MRI-SCAB or SQPV. In the absence of H4, all viruses produced plaques,
or in the case of SQPV destroyed the monolayer (Fig. 7A). Strikingly, treatment with H4
at 20, 80, or 200 nM completely attenuated plaque formation by all of the viruses (Fig.
7A). These results demonstrate that the bisbenzimide H4 is a broad-range inhibitor of
poxvirus infection across different genera.
While we had shown previously that H4 did not affect plaque formation by human
adenovirus (52), we wanted to test the impact of H4 on other viruses, including herpes
simplex virus 1 (HSV-1), which replicates in the nucleus (53), and RNA viruses, which
replicate either in the nucleus (inﬂuenza A virus [IAV]) or the cytoplasm (vesicular
stomatitis virus [VSV] or Semliki Forest virus [SFV]). When cells were infected with these
viruses in the presence of 20 or 200 nM H4, expression of GFP from reporter viruses was
not signiﬁcantly impacted regardless of the concentration used (Fig. 7B). We conclude
that bisbenzimides are rather selective inhibitors against poxviruses and do not affect
a broad range of unrelated viruses.
FIG 7 Poxviruses are acutely sensitive to H4 inhibitory activity. (A) Fetal lamb skin cell monolayers were
infected with VACV or ORF-11 (100 PFU), MRI-SCAB (500 PFU), or squirrelpox virus (SQPV [1,000 PFU]).
Cells were ﬁxed and plaques visualized by crystal violet staining at 3 days (VACV), 4 days (ORF-11), or 7
days (MRI-SCAB and SQPV). Experiments were performed in triplicate; representative images are shown.
(B) HeLa cells were infected with EGFP-expressing variants of VACV WR, herpes simplex virus 1 (HSV-1),
inﬂuenza A virus (IAV), vesicular stomatitis virus (VSV), or Semliki Forest virus (SFV). For each, infection
was allowed to proceed for 6 to 8 h, after which cells were analyzed for EGFP expression by ﬂow
cytometry. Experiments were performed in triplicate; the percentage of infection relative to untreated
(NoT) controls is displayed as the mean  SD.
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DISCUSSION
Bisbenzimides are a class of ﬂuorescent dyes commonly used in ﬂow cytometry and
ﬂuorescence microscopy to identify cell nuclei. Bisbenzimides stain DNA in the nucleus
and cytoplasmic organelles, such as mitochondria and chloroplasts (36). Here we
demonstrate that a range of bisbenzimides are potent inhibitors of poxvirus infection.
We used a variety of virological assays to determine the stage of the VACV life cycle
impacted by H4, the most effective Hoechst derivative tested. We found that H4 did not
inhibit infection by acting on extracellular viral particles or by targeting the early stages
of the virus life cycle, including EGE and DNA uncoating. Analysis of viral early gene
(EG), IG, and LG transcription, DNA replication site formation, and viral DNA synthesis
indicated that H4 blocked IG and LG transcription as well as DNA replication in a
dose-dependent manner. H4 strongly inhibited the production of infectious VACV
particles, and plaque formation was impeded in its presence.
Our results indicate that the effectiveness of bisbenzimides against poxviruses
correlates with the accessibility of the viral DNA to solutes. We found that the Hoechst
compounds did not affect the infectivity of VACV particles when the particles were
intact—that is, when they were outside cells. The compounds were effective after viral
DNA was released from the capsid into the cytosol, where it is replicated. Consistent
with this, the EC50 of H4 against EGE, which occurs when the viral core is largely intact,
was 20-fold higher than the EC50 for IGE and LGE, which only occurs from exposed viral
DNA. EG transcription occurs within cytoplasmic viral cores prior to genome uncoating,
while intermediate and late gene transcription occurs in the cytoplasm after viral
genome replication (54). High concentrations of H4 could impact EGE during the
activation of cytosolic cores, which expand when EG transcription occurs (55–58). We
speculate that core expansion may lead to increased accessibility of the VACV genomes
within. That early, intermediate, and late VACV mRNAs are all translated in the cyto-
plasm on host ribosomes makes it unlikely that bisbenzimides impact translation of
viral proteins.
We noted that the inhibitory efﬁcacy of the bisbenzimides correlated with their
lipophilicity: H4  H8  H5 (Fig. 1A). Lipophilicity largely dictates the binding of
bisbenzimides to double-stranded DNA via hydrophobic interactions with adenosine-
threonine (A  T)-rich regions (25, 59, 60). Since poxviruses with differential genomic
A  T content—that is VACV (67% A  T), ORFV (36% A  T), and SQPV (33% A  T)
(61)—display similar sensitivities to H4, it is unlikely that poxviruses are susceptible to
bisbenzimides simply due to their high A  T content. It is more likely that the solute
accessibility of the viral genome and the association of DNA binding proteins dictate
susceptibility of the virus to the Hoechst compounds.
Remarkably, despite their effectiveness against poxviruses the Hoechst bisbenzim-
ides tested had no effect on infection by other DNA viruses, such as adenovirus or
herpesvirus. As opposed to poxviruses, herpesviruses and adenoviruses deliver their
infectious incoming DNA genomes directly into the nucleus, where they are transcribed
and replicated (48, 53, 62–64). It is possible that bisbenzimides do not efﬁciently bind
to the nuclear DNA of adenovirus and herpesvirus due to the spatial proximity of host
DNA, which acts as an efﬁcient local avidity trap for the bisbenzimides. In this scenario,
bisbenzimides used at low nanomolar, nontoxic concentrations would be more likely to
bind to host DNA than viral DNA.
While selection of VACV variants resistant to either of the antipoxvirus agents
cidofovir and ST-246 is readily possible (16, 65), we were unable to isolate a
bisbenzimide-resistant VACV in up to 20 passages at different concentrations of H4
(data not shown). This is consistent with our ﬁnding that H4 targets at least two viral
processes. Low concentrations of H4 inhibited IG and LG transcription, while higher
concentrations of H4 also blocked viral DNA replication. IG and LG transcription
inhibition at low H4 concentrations could occur since the intermediate and late
promoters are AT rich (66), and H4 preferentially binds to AT-rich dsDNA. The presence
of small highly condensed viral DNA replication sites observed in the presence of high
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concentrations of H4 and the observation that VACV topoisomerase DNA unwinding
activity is unaffected in vitro (data not shown) (67) suggest a model in which bisben-
zimides block DNA replication by coating cytoplasmic VACV genomes.
In sum, we show that bisbenzimide compounds are highly speciﬁc for inhibiting
poxvirus infections at low apparent cytotoxicity. It is possible that the bisbenzimides
tested here are also effective against divergent members of the nucleocytoplasmic
large DNA viruses that replicate exclusively in the cytoplasm (68). Bisbenzimide com-
pounds have been used in mice with potential antitumor effects (30) and were tested
in a phase I-phase II advanced pancreatic carcinoma study in humans (69). Notably, in
both cases bisbenzimides were well tolerated. While the in vivo efﬁcacy of bisbenzim-
ides against poxvirus infection has not been determined, the dual mechanism of
inhibition—that is, I/L gene expression and viral DNA replication—appears to be a high
barrier against the emergence of viral resistance. This makes it tempting to speculate
that bisbenzimides may serve as attractive antipoxvirus drugs, either alone or in
combination with CMX001 and ST-246 (70).
MATERIALS AND METHODS
Cell culture and reagents. All cell lines used were cultivated as monolayers at 37.0°C and 5.0% CO2.
Cells were cultured in Dulbecco’s modiﬁed Eagle’s medium (DMEM [Gibco, Life Technologies, Switzer-
land]). HeLa cells (ATCC) and L929 mouse subcutaneous areolar and adipose cells (ATCC) were cultivated
in DMEM with the addition of 10% fetal bovine serum (FBS [Sigma]), 2 mM GlutaMAX (Life Technologies),
and 1% penicillin-streptomycin (Pen-Strep [Sigma]). Cercopithecus aethiops kidney epithelial cells (BSC40;
ATCC) were cultivated in DMEM with 10% FBS, 2 mM GlutaMAX, 1% nonessential amino acid mix (NEAA
[Sigma]), and 1 mM sodium pyruvate (NaPyr [Sigma]). Cells of the HDFn human foreskin ﬁbroblast cell
line (Invitrogen) were cultivated in DMEM containing 5% FBS. Fetal lamb skin cells were cultivated in
medium 199 (Sigma) with 2% glutamine, 0.16% sodium hydrogen carbonate, 10% tryptose phosphate
broth, and 10% FBS.
VACV and parapoxvirus strains and virus puriﬁcation. Vaccinia virus strain Western Reserve (VACV
WR) was used throughout (71, 72). These strains were either wild type (WT) or transgenic containing
early/late EGFP (E/L EGFP VACV WR), early EGFP (E EGFP VACV WR), intermediate EGFP (I EGFP VACV WR),
or late EGFP (L EGFP VACV WR). All VACV mature virions (MVs) were puriﬁed from cytoplasmic lysates by
being pelleted through a 36% sucrose cushion for 90 min at 18,000  g. The virus pellet was resuspended
in 10 mM Tris (pH 9.0) and subsequently banded on a 25 to 40% sucrose gradient at 14,000  g for 45 min.
Following centrifugation, the viral band was collected by aspiration and concentrated by pelleting at
14,000  g for 45 min. MVs were resuspended in 1 mM Tris (pH 9.0), and the titer was determined for
PFU per milliliter as previously described (73). The parapoxvirus strains used include a tissue culture-
adapted strain, ORF-11, a nonadapted strain, MRI-SCAB, and squirrelpox virus (SQPV). IAV was obtained
from Yohei Yamauchi, SFV and VSV were obtained from Giuseppe Balistreri, and HSV-1 was obtained
from Cornel Fraefel.
Inhibitors, dyes, antibodies, and plasmids. Cycloheximide (CHX [Sigma]) was used at 50 M,
cytosine arabinoside (cytarabine, or AraC [Sigma]) was used at 10 M. Bisbenzimides H4, H8, and H5
(Sigma) were dissolved in water and used as described in the respective experiments. Rabbit polyclonal
anti-EGFP was used at a 1:1,000 dilution. Anti-I3 antibody (generously provided by Jakomine Krijnse
Locker; Institute Pasteur) was used at 1:500. All secondary antibodies (goat anti-rabbit-AF488 and goat
anti-rabbit-AF594 [Invitrogen]) were used at 1:1,000.
Plaque 2.0 assay. BSC40 cells were cultivated as monolayers in 96-well imaging plates (Greiner
Bio-One, Germany) and inoculated with a serial dilution of either E/L EGFP VACV WR or E/L EGFP VACV
IHD-J. One hour postinfection, the inoculum was removed and replaced with medium (nontreated
control) or a respective dilution of an experimental compound in the medium. Twenty-four hours
postinfection, plates were ﬁxed with 4% paraformaldehyde (PFA) and stained with Hoechst nuclear stain.
Plates were imaged using ImageXpress XL Micro epiﬂuorescent high-throughput microscope (Molecular
Devices, USA) with a 4 air objective (Nikon, Japan) in a tile mode allowing full well reconstruction.
Image processing and analysis were performed using Plaque 2.0 software (41). The experiment was
performed in three technical replicas (triplicate).
Early, intermediate, and late VACV gene expression analysis. HeLa or BSC40 cells in 24-well
plates were infected with E EGFP VACV WR and L EGFP VACV WR at a multiplicity of infection (MOI) of
5 together with H4 at different concentrations. To quantify EGE or IGE and LGE, cells were infected for
6 or 8 h, respectively. Cells were detached with 0.05% trypsin-EDTA and ﬁxed in 4% formaldehyde for 15
min. After centrifugation at 500  g for 5 min, the cell pellets were resuspended in 400 l ﬂuorescence-
activated cell sorter (FACS) buffer. A BD Bioscience FACSCalibur ﬂow cytometer was used for analysis, and
10,000 cells per condition were measured.
Virus titrations by plaque assay. Viruses were diluted in the medium appropriate for the cell line,
and 250 or 500 l of this virus dilution was added to HeLa or fetal lamb skin cell monolayers in 6-well
plates. The plates were rocked every 15 min, and after 1 h, medium was aspirated and cells fed with full
medium containing the indicated compound concentrations. The cells were then incubated at 37°C for
3, 4, or 7 days (as indicated) before undergoing staining with 0.1% crystal violet in 3.7% PFA.
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Twenty-four-hour virus yield. HeLa cells in 12-well plates were infected at an MOI of 1 in the
presence of the compound. After 24 h, cells were collected and centrifuged, and the pellet was
resuspended in 100 l 1 mM Tris (pH 9.0). Cells were freeze-thawed three times to lyse the cells, and the
virus solution was subjected to serial titration to determine the PFU per milliliter.
Add-in and washout assays. HeLa cells were grown in 12-well plates and infected with WT VACV
WR at an MOI of 1. For washout experiments, infection was performed in the presence of 80 nM H4. At
the indicated time point, the cells were washed ﬁve times with medium and infection was allowed to
proceed in the absence of compound. For add-in experiments, medium containing 80 nM H4 was added
to the cells at the indicated time points. For both experiments, at 24 hpi, cells were collected and titers
determined as described above.
Pretreatment of virus particles with H4. Viruses expressing EGFP from early or late promoters were
preincubated with 20 or 80 nM H4 for the indicated times at room temperature. The virus particles were
washed three times in medium and used to infect HeLa cells. Similarly to early and late gene proﬁling,
infection was stopped after 6 to 8 hpi, and infection was analyzed by ﬂow cytometry.
Prereplication site visualization. HeLa cells were infected with WT VACV at an MOI of 10 in the
presence of AraC and 20, 80, or 200 nM H4. At 5 hpi, cells were ﬁxed, nuclei stained with DAPI, and
prereplication sites visualized by immunoﬂuorescence staining against VACV I3. Images were acquired by
confocal microscopy, and maximum projections were generated from 10 z-stacks. The number of
prereplication sites per cell in the presence of 20, 80, or 200 nM H4 was determined by spot detection
of the maximum intensity projections (spots larger than 5 pixels) with the Fiji platform. Cells treated with
CHX and AraC alone served as controls for genome uncoating and replication site formation, respectively.
Replication site formation. HeLa cells were infected with WT VACV at an MOI of 5 in the presence
of 20, 80, or 200 nM H4. At 8 hpi, cells were ﬁxed and VACV replication sites visualized by staining with
DAPI. The percentage of cells containing replication sites was quantiﬁed by manual counting due to the
shape and size variation of replication sites under the various conditions. AraC sample served as a control
for inhibition of DNA replication site formation.
EdU accumulation. HeLa cells were infected with WT VACV at an MOI of 10. After 1 h of virus binding
in DMEM, the medium was changed to 10% DMEM containing 1 M EdU in the presence or absence of
H4 (20, 80, or 200 nM). At 8 hpi, cells were ﬁxed with 4% PFA and stained using the Click-iT EdU imaging
kit (Thermo Scientiﬁc) and Hoechst to visualize cell nuclei. Cells were imaged using confocal microscopy
and analyzed using CellProﬁler/KNIME software. Brieﬂy, the intensity of EdU staining per sample was
determined after background subtraction and exclusion of nuclei by image segmentation.
Viral DNA quantiﬁcation by qPCR. HeLa cell monolayers were infected with WR (MOI of 10) in the
absence or presence of H4 for 8 h. Total DNA was extracted using the Qiagen DNeasy blood and tissue
kit according to the manufacturer’s instruction. Total DNA concentrations were assessed using a
Nanodrop spectrophotometer, and a portion of total DNA was used in the qPCR assay using Mesa Blue
qPCR MasterMix Plus for the SYBR assay system (Eurogentec) with the C11R primer (5=-AAACACACACT
GAGAAACAGCATAAA-3= and 5=-ACTATCGGCGAATGATCTGATTA-3=). The concentration of viral DNA was
determined by plotting against a standard curve of VACV DNA from puriﬁed virions.
RT-PCR. HeLa cell monolayers were infected with WR (MOI of 10) in the absence or presence of H4
for 2, 4, or 8 h. Total RNA was harvested from infected cells using the Qiagen RNeasy kit according to the
manufacturer’s instructions. Subsequently, 1 l of total RNA was reverse transcribed into single-stranded
cDNA with SuperScript II reverse transcriptase (Thermo Fisher Scientiﬁc) and oligo(dT) primers. Ampli-
ﬁcation of J2 (early) from 2-h samples, G8 (intermediate) from 4-h samples, F17 (late) from 8-h samples,
and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cDNA from all time points was performed by
qPCR (Mesa Blue qPCR MasterMix Plus for SYBR assay; Eurogentec) using primers speciﬁc for VACV J2R
(5=-TACGGAACGGGACTATGGAC-3= and 5=-GTTTGCCATACGCTCACAGA-3=), G8R (5=-AATGTAGACTCGACG
GATGAGTTA-3= and 5=-TCGTCATTATCCATTACGATTCTAGTT-3=), F17R (5=-ATTCTCATTTTGCATCTGCTC-3=
and 5=-AGCTACATTATCGCGATTAGC-3=), and GAPDH (5= AAGGTCGGAGTCAACGGATTTGGT-3= and 5=-
ACAAAGTGGTCGTTGAGGGCAATG-3=). Viral mRNA threshold cycle (CT) values are displayed as abundance
normalized against GAPDH.
Inﬂuenza A virus, Semliki Forest virus, vesicular stomatitis virus, and herpes simplex virus 1
infections. EGFP-expressing variants of the indicated viruses were used for these experiments. For each,
HeLa cells were infected at an MOI of 5 in the presence of 20 or 200 nM H4 and cells were prepared for
ﬂow cytometry analysis between 6 and 8 hpi.
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